Search

Your search keyword '"Hernandez Boluda J"' showing total 4 results
Start Over Author "Hernandez Boluda J" Topic hematology
4 results on '"Hernandez Boluda J"'

1. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry

Author

Hernandez-Boluda J, Martinez-Cuadron D, Pereira A, Rodriguez-Veiga R, Boluda B, Gil C, Casal-Marini S, Serrano J, Martinez-Lopez J, Bergua J, Algarra L, Bernal T, Lopez-Lorenzo J, Colorado M, Lopez A, Tormo M, Sayas M, Trigo F, Lopez-Pavia M, Perez-Simon J, Lavilla-Rubira E, Rodriguez-Medina C, Rodriguez-Gutierrez J, Sanz-Caballer M, Montesinos P, and PETHEMA group

Subjects
Cancer Research, Acute leukemia, Survival, Hematopoietic Stem Cell Transplantation, Myeloproliferative neoplasm, Hematology, Myelodysplastic-Myeloproliferative Diseases, Acute leukemia, Myelodysplastic/myeloproliferative neoplasm, Myeloproliferative neoplasm, Survival, Treatment, Treatment, Leukemia, Myeloid, Acute, Oncology, Myelodysplastic Syndromes, Myelodysplastic/myeloproliferative neoplasm, Humans, Registries
Abstract

PETHEMA group., Treatment of acute myeloid leukemia (AML) evolving from myeloproliferative (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) is challenging. We evaluated disease characteristics, treatment patterns and outcomes in 372 patients diagnosed with AML after MPN or MDS/MPN over a 27-year period. Frontline treatment was intensive chemotherapy (38%), hypomethylating agents [HMAs] (17%), non-intensive chemotherapy (14%), and supportive care (31%). Median overall survival was 4.8 months, with a 5-year survival rate of 4%. Median survival was 2.8, 3.9 and 8.3 months for the 1992-2010, 2011-2015 and 2016-2019 periods, respectively (test for trend p

Published
2022

2. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

Author

Luna, A, Pérez-Lamas, L, Boque, C, Giraldo, P, Xicoy, B, Ruiz Nuño, C, Vega, M Moreno, Alvarez-Larrán, A, Salamanca, A, García-Noblejas, A, Vall-Llovera, F, Villalon, L, De Las Heras, N, Ramila, E, Pérez-Encinas, M, Cuevas, B, Perez-Lopez, R, Sanchez-Guijo, F, Jiménez-Velasco, A, Lakhwani, S, Casado, L Felipe, Rosell, A, Escola, A, Fernández, M J, Garcia-Hernandez, C, Cervero, C, Mora, E, Sagüés, M, Suarez-Varela, S, Vélez, P, Carrascosa Mastell, P, Bitaube, R F, Serrano, L, Cortes, M, Vera Goñi, J A, Steegmann, J L, de Soria, V Gomez Garcia, Alonso-Dominguez, J M, Araujo, M Colorado, Coll, A Paz, Hernandez-Boluda, J C, García-Gutiérrez, V, [Luna A, Pérez-Lamas L] Hematology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. [Boque C] Institut Catala d’Oncologia, Hospital Duran Y Reynals, L’Hospitalet de Llobregat, Barcelona, Spain. [Giraldo P] Hospital Quirón Zaragoza, Zaragossa, Spain. [Xicoy B] Institut Català d’Oncologia-Hospital Germans Trias I Pujol, Badalona, Spain. [Ruiz Nuño C] Hospital Regional Universitario de Málaga, Málaga, Spain. [Cortes M] Hospital General de Granollers, Granollers, Spain, and Hospital General de Granollers

Subjects
Niacinamide, Leukemia, Inhibitors, Fusion Proteins, bcr-abl, Imidazoles, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive [DISEASES], Antineoplastic Agents, Hematology, General Medicine, Asciminib, Other subheadings::Other subheadings::/drug therapy [Other subheadings], acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos [COMPUESTOS QUÍMICOS Y DROGAS], Pyridazines, Leucèmia - Tractament, Inhibidors enzimàtics, Drug Resistance, Neoplasm, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors [CHEMICALS AND DRUGS], Humans, Pyrazoles, enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::trastornos mieloproliferativos::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES], Protein Kinase Inhibitors, Retrospective Studies
Abstract

Failure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in patients with chronic myeloid leukemia (CML). Asciminib, recently approved by the US Federal Drug Administration, has demonstrated in clinical trials a good efficacy and safety profile after failure of 2GTKI. However, no study has specifically addressed response rates to asciminib in ponatinib pretreated patients (PPT). Here, we present data on responses to asciminib from 52 patients in clinical practice, 20 of them (38%) with prior ponatinib exposure. We analyzed retrospectively responses and toxicities under asciminib and compared results between PPT and non-PPT patients.After a median follow-up of 30 months, 34 patients (65%) switched to asciminib due to intolerance and 18 (35%) due to resistance to prior TKIs. Forty-six patients (88%) had received at least 3 prior TKIs. Regarding responses, complete cytogenetic response was achieved or maintained in 74% and 53% for non-PPT and PPT patients, respectively. Deeper responses such as major molecular response and molecular response 4.5 were achieved in 65% and 19% in non-PPT versus 32% and 11% in PPT, respectively. Two patients (4%) harbored the T315I mutation, both PPT.In terms of toxicities, non-PPT displayed 22% grade 3–4 TEAE versus 20% in PPT. Four patients (20% of PPT) suffered from cross-intolerance with asciminib as they did under ponatinib.Our data supports asciminib as a promising alternative in resistant and intolerant non-PPT patients, as well as in intolerant PPT patients; the resistant PPT subset remains as a challenging group in need of further therapeutic options.

Published
2022

3. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

Author

Alvarez-Larran A, Angona A, Andrade-Campos M, Noya M, Gomez-Casares M, Cuevas B, Caballero G, Garcia-Hernandez C, Garcia-Gutierrez V, Palomino A, Ferrer-Marin F, Mata-Vazquez M, Moreto A, Magro E, Murillo I, Alonso-Dominguez J, Guerra J, Guerrero L, Raya J, Perez-Encinas M, Carreno-Tarragona G, Fox L, Pastor-Galan I, Bellosillo B, Hernandez-Boluda J, and MPN Spanish Grp GEMFIN

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Genotype, genotype, Mutation, Missense, essential thrombocythaemia, Gastroenterology, myeloproliferative neoplasms, Hydroxycarbamide, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Humans, Hydroxyurea, In patient, Registries, Child, Aged, haematological response, Aged, 80 and over, therapy, Haematological response, business.industry, Essential thrombocythemia, Hematology, Anagrelide, Janus Kinase 2, Middle Aged, medicine.disease, Amino Acid Substitution, Treatment modality, Median time, Spain, 030220 oncology & carcinogenesis, Quinazolines, Female, calreticulin mutation, business, Calreticulin, 030215 immunology, medicine.drug, Follow-Up Studies, Thrombocythemia, Essential
Abstract

The present study assessed the criteria for initiating cytoreduction and response to conventional therapies in 1446 patients with essential thrombocythemia (ET), 267 (17%) of which wereCALR-mutated. In low risk patients, time from diagnosis to cytoreduction was shorter inCALR-positive than in the other genotypes (2 center dot 8, 3 center dot 2, 7 center dot 4 and 12 center dot 5 years forCALR,MPL,JAK2V617F and TN, respectively,P < 0 center dot 0001). A total of 1104 (76%) patients received cytoreductive treatment with hydroxycarbamide (HC) (n = 977), anagrelide (n = 113), or others (n = 14). The estimated cumulative rates of complete haematological response (CR) at 12 months were 40 % and 67% inCALRandJAK2V617F genotypes, respectively. Median time to CR was 192 days forJAK2V617F, 343 for TN, 433 forMPL, and 705 forCALRgenotypes (P < 0 center dot 0001). Duration of CR was shorter inCALR-mutated ET than in the remaining patients (P = 0 center dot 003). InCALR-positive patients, HC and anagrelide had similar efficacy in terms of response rates and duration.CALR-mutated patients developed resistance/intolerance to HC more frequently (5%, 23%, 27% and 15% forJAK2V617F,CALR,MPLand TN, respectively;P < 0 center dot 0001). In conclusion, conventional cytoreductive agents are less effective inCALR-mutated ET, highlighting the need for new treatment modalities and redefinition of haematologic targets for patients with this genotype.

Published
2020

4. Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT

Author

Nicolaus Kröger, Aleksandar Radujkovic, Jakob Passweg, Marie Robin, Tomasz Czerw, Patrick Hayden, Emanuele Angelucci, Alessandro Rambaldi, Katya Mauff, Liesebeth C. de Wreede, Ibrahim Yakoub-Agha, Juan Carlos Hernández-Boluda, Jiri Mayer, Yves Chalandon, Matthias Stelljes, Donal P. McLornan, Uwe Platzbecker, Mitja Nabergoj, Stephen P. Robinson, Xavier Poiré, Linda Koster, Fabio Ciceri, Søren Lykke Petersen, Marco Ladetto, Fridrich Stölzel, Nabergoj, M., Mauff, K., Robin, M., Kroger, N., Angelucci, E., Poire, X., Passweg, J., Radujkovic, A., Platzbecker, U., Robinson, S., Rambaldi, A., Petersen, S. L., Stolzel, F., Stelljes, M., Ciceri, F., Mayer, J., Ladetto, M., de Wreede, L. C., Koster, L., Hayden, P. J., Czerw, T., Hernandez-Boluda, J. C., Mclornan, D., Chalandon, Y., Yakoub-Agha, I., UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service d'hématologie, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Paris - UFR Médecine Paris Centre [Santé] (UP Médecine Paris Centre), Université de Paris (UP), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), UFR Médecine [Santé] - Université Paris Cité (UFR Médecine UPCité), and Université Paris Cité (UPCité)

Subjects
medicine.medical_specialty, Graft failure, Transplantation Conditioning, [SDV]Life Sciences [q-bio], Primary Myelofibrosis / therapy, Graft vs Host Disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Neoplasms, medicine, Humans, In patient, Sibling, Myelofibrosis, Retrospective Studies, ddc:616, Transplantation, business.industry, Incidence (epidemiology), Haematopoietic cell transplantation, Hematopoietic Stem Cell Transplantation, Retrospective cohort study, Hematology, Middle Aged, medicine.disease, 3. Good health, surgical procedures, operative, Primary Myelofibrosis, 030220 oncology & carcinogenesis, Chronic gvhd, business, 030215 immunology
Abstract

International audience; Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We retrospectively analyzed 216 patients undergoing a second allo-HCT for either relapse (56%) or graft failure (31%) between 2010 and 2017. Median age was 57.3 years (range 51–63). The same donor as for the first allo-HCT was chosen in 66 patients (31%) of whom 19 received an HLA-identical sibling donor, whereas a different donor was chosen for 116 patients (54%). Median follow-up was 40 months. Three-year overall survival (OS) and relapse-free survival (RFS) were 42% and 39%, respectively. Three-year non-relapse mortality (NRM) and relapse rates were 36% and 25%, respectively. Grade II-IV and III-IV acute GVHD occurred in 25% and 11% of patients, respectively, and the 3-year incidence of chronic GVHD was 33% including 14% for extensive grade. Graft-failure incidence at 1 year was 14%. In conclusion, our data suggest that a second allo-HCT is a potential option for patients failing first allo-HCT for MF albeit careful patient assessment is fundamental to identify individual patients who could benefit from this approach.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results